pharmacotherapy in gca and pmr l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Pharmacotherapy in GCA and PMR PowerPoint Presentation
Download Presentation
Pharmacotherapy in GCA and PMR

Loading in 2 Seconds...

play fullscreen
1 / 16

Pharmacotherapy in GCA and PMR - PowerPoint PPT Presentation


  • 192 Views
  • Uploaded on

Pharmacotherapy in GCA and PMR. Dr Tristan Learoyd Sunderland School of Pharmacy. Disease. Polymyalgia Rheumatica and/or Giant Cell Arteritis (also known as Temporal Arteritis ) physical and psychological effects Main symptoms are pain and unreasonable fatigue

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Pharmacotherapy in GCA and PMR' - molly


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
pharmacotherapy in gca and pmr

Pharmacotherapy in GCA and PMR

Dr Tristan Learoyd

Sunderland School of Pharmacy

disease
Disease
  • PolymyalgiaRheumatica and/or Giant Cell Arteritis (also known as Temporal Arteritis)
  • physical and psychological effects
  • Main symptoms are pain and unreasonable fatigue
  • morning stiffness which eases as the day progresses is a significant factor along with severe pain in the shoulders, thighs and pelvic area
  • Aetiology unknown
  • Patients can be on complicated medication regimes
  • Chronic condition requiring long term therapy
pharmacotherapy
Pharmacotherapy
  • Many agents used
  • Steriods: prednisolone predominantly
  • Bone protectants: alendronate
  • Non-steroidal anti-inflammatories (in passing)
prednisolone
Prednisolone
  • Start at a high dose and then reduced to maintenance
  • Slow reduction
  • 60 mg reduced as symptoms and erythrocyte sedimentation rate subsides
  • Steady state pharmacokinetics
  • Plasma half-life of prednisolone much shorter than biologic half-life (2.5-4 hours)
inflammation and pain
Inflammation and Pain

The outside of our cells is made of a chemical called phospholipid

Human Cell

Arachdonic acid is formed by the phospholipid – steroids stop this

Arachdonic Acid

An enzyme is a molecule that transforms chemicals

COX

ENZYME

Non-steroidals, such as diclofenac stop COX forming PG

PG1 protects the stomach lining and other membranes

PG2 causes inflammation and pain but protects the heart

PG1

PG2

immunosupression
Immunosupression

Attraction of white blood cells

Human cell

Cytokine

Cell damage

Corticosteroid

immunosupression by corticosteroids
Immunosupression by Corticosteroids
  • Immunosupression by stimulating intracellular glucocorticoid receptors which interferes with RNA and DNA synthesis and thus cytokine production
  • Large initial doses as the first action of corticosteroids on the redistribution of lymphocytes to bone marrow rather than for cell lysis. High doses also inhibit t-cell production
prednisolone9
Prednisolone
  • Glucocorticoid effects with minimal mineralocorticoid effects

- Little water retention while acting on inflammation and pain

  • Suitable oral formulation

- Is absorbed across the stomach lining

  • Crosses blood-brain barrier
  • Use in GCA
the blood brain barrier
The blood brain barrier
  • GCA in particular requires vascular permeation to allow vasodilatation
  • A problem to modern therapy that relies on large proteins
  • Steroids can pass as lipophilic and relatively small
enteric coating
Enteric coating
  • A coating of Cellulose acetate phthalate
  • A glossing of ethyl cellulose.
  • Enteric coating releases agents in the jejunum and duodenum and not in the stomach
  • But steroids act systemically
  • Hypocrisy?
enteric coating12
Enteric Coating

Despite the enteric coating preventing release in the stomach the drug is introduced into systemic circulation and protective factors are removed as a side-effect of the steroid’s action

STOMACH

BLOOD VESSEL

osteoporosis
Osteoporosis
  • Prednisolone has a danger of osteoporosis if taken over long periods of time, due to the reduction in osteoblast formation
  • Osteoblasts are bone cells
  • Bone is constantly recycled
  • The outside of bone is spongy
  • Has direct effect suppressing production and indirect by hormone inhibition
  • Testosterone is produced in men and oestrogen in women, the hormones are involved in signalling bone cell production
  • Due to corticosteroid feedback on the pituitary gland in the brain less testosterone and oestrogen are produced
  • Due to reduced oestrogen and testosterone release, the reduction in bone cell production causes a thinning of the bone as cells are removed but not replaced
bone protection
Bone protection
  • Calcium and vitamin D involved in osteoblast (bone cell) formation and a high intake of both is recommended
  • Biphosphonates reduce osteoblast growth and turnover
  • Calcitonin is involved with parathyroid hormone regulation of bone turnover and calcium usage
  • Strontium stimulates bone production and reduces turnover
other steroid problems
Other steroid Problems
  • Diabetes can result from prolonged use
  • Ulceration
  • Muscle wasting
  • Haematological effect methotrexate
  • Cushing’s syndrome
  • Diminished adrenocortical function over time: so during surgery and trauma additional steroid may be required
  • Anaesthetists must know of steroid use to prevent drop in blood pressure under anaesthetic
some common steroid interactions
Some Common Steroid interactions
  • Enhanced warfarin effects
  • Carbamazepine induces metabolism
  • Phenytion inducement